“Golimumab for Adherence in Rheumatoid Arthritis”
The purpose of this study is to determine if non-adherence to Rheumatoid Arthritis (RA) drugs in participants treated with biologic disease modifying anti-rheumatic drugs (DMARDs) is associated with a greater incidence of disease in clinical practice.
Biological - Golimumab
Participants will receive golimumab as a part of clinical practice.
Golimumab for Adherence in Rheumatoid Arthritis